A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease
Clinical Pharmacology & Therapeutics · 2024-03 · 115 (3) · 565-575
DOI: 10.1002/cpt.3147 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 24.01.2024. Verfasst von Fred Reid und 20 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Development, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Interleukin-33, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: COPD
Abstract (Originalsprache)
Tozorakimab is a human monoclonal antibody that neutralizes interleukin (IL)‐33. IL‐33 is a broad‐acting epithelial “alarmin” cytokine upregulated in lung tissue of patients with chronic obstructive pulmonary disease (COPD). This first‐in‐human, phase I, randomized, double‐blind, placebo‐controlled study (NCT03096795) evaluated the safety, tolerability, pharmacokinetics (PKs), immunogenicity, target engagement, and pharmacodynamics (PDs) of tozorakimab. This was a 3‐part study. In part 1, 56 healthy participants with a history of mild atopy received single escalating doses of either intravenous or subcutaneous tozorakimab or placebo. In part 2, 24 patients with mild COPD received multiple ascending doses of subcutaneous tozorakimab or placebo. In part 3, 8 healthy Japanese participants received a single intravenous dose of tozorakimab or placebo. The safety data collected included treatment‐emergent adverse events (TEAEs), vital signs, and clinical laboratory parameters. Biological samples for PKs, immunogenicity, target engagement, and PD biomarker analyses were collected. No meaningful differences in the frequencies of TEAEs were observed between the tozorakimab and placebo arms. Three tozorakimab‐treated participants with COPD experienced treatment‐emergent serious adverse events. Subcutaneous or intravenous tozorakimab demonstrated linear, time‐independent PKs with a mean half‐life of 11.7–17.3 days. Treatment‐emergent anti‐drug antibody frequency was low. Engagement of tozorakimab with endogenous IL‐33 in serum and nasal airways was demonstrated. Tozorakimab significantly reduced serum IL‐5 and IL‐13 levels in patients with COPD compared with placebo. Overall, tozorakimab was well tolerated, with a linear, time‐independent serum PK profile. Additionally, biomarker studies demonstrated proof of mechanism. Overall, these data support the further clinical development of tozorakimab in COPD and other inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Development, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Medicines Evaluation Unit, Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK.
- Parexel International, Early Phase Clinical Unit, Northwick Park Hospital, Harrow, UK.
- Early Biostatistics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Barcelona, Spain.
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Zitieren
APA
Reid, F., Singh, D., Albayaty, M., Moate, R., Jimenez, E., Sadiq, M. W., Howe, D., Gavala, M., Killick, H., Williams, A., Krishnan, S., Godwood, A., Shukla, A., Hewitt, L., Lei, A., Kell, C., Pandya, H., Newcombe, P., White, N., …, & Cohen, E. S. (2024). A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease. Clinical Pharmacology & Therapeutics, 115(3), 565-575. https://doi.org/10.1002/cpt.3147
Vancouver
Reid F, Singh D, Albayaty M, Moate R, Jimenez E, Sadiq MW, et al. A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease. Clinical Pharmacology & Therapeutics. 2024;115(3):565-575. doi:10.1002/cpt.3147
BibTeX
@article{Reid2024,
author = {Reid, Fred and Singh, Dave and Albayaty, Muna and Moate, Rachel and Jimenez, Eulalia and Sadiq, Muhammad Waqas and Howe, David and Gavala, Monica and Killick, Helen and Williams, Adam and Krishnan, Surekha and Godwood, Alex and Shukla, Animesh and Hewitt, Lisa and Lei, Alejhandra and Kell, Chris and Pandya, Hitesh and Newcombe, Paul and White, Nicholas and Scott, Ian C and Cohen, E Suzanne},
title = {A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
volume = {115},
number = {3},
pages = {565--575},
doi = {10.1002/cpt.3147}
}
EUVIMED